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One of the more difficult topics to discuss concerning the ethics of healthcare is distributive 
justice—the fair distribution of benefits, risks, and costs. This moral principle is becoming one of the 
more important issues in oncology care because of the rising cost of cancer therapies and the significant 
financial toxicities that are being inflicted on patients, taxpayers, and the health system at large. As higher 
numbers of cancer patients are filing for bankruptcy secondary to medical costs, many oncologists are 
wondering whether there is a way to reconcile quality care and affordability. 
The market for anticancer drugs is considerable and has been growing at a rapid rate. Global 
market spending for anticancer pharmaceuticals alone increased from $71 billion in 2008 to $91 billion in 
2013.[1] In the United States, approximately 5% of the nation’s gross domestic product was spent on 
healthcare in 1965. By 2004, that percentage had increased to 16%, and today it is nearing 20%.[2] 
However, despite the growing price of and the increased spending on anticancer pharmaceuticals, the 
progression-free survival (PFS) and overall survival (OS) benefits for patients have been minimal. The 
median improvement in PFS for new drugs between 2002 and 2014 was found to be 2.5 months, and the 
median improvement in OS was 2.1 months.[3] One of the reasons stated for such a large price tag on 
cancer therapeutics is that this is a direct consequence of the cost of developing new cancer therapies. 
However, studies have found that, of the new cancer therapeutics brought to market between 2002 and 
2014, “74% of them had an overlapping mechanism of action with others yet approved or still in clinical 
development.”[4] It would seem logical that developing a “me-too”[3] drug with a mechanism similar to 
that of an already approved drug decreases the risk of drug failure while adding the benefit of less 
developmental cost and the potential to get the drug to market quicker, thus allowing for increased profits. 
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However, it does not increase the variability of anticancer agents, and does little to further our ability to 
make a more significant impact on cancer overall. Because healthcare does not fall under the influence of 
free market forces,[5] the competition of similar products flooding the market has done nothing to drop 
the prices of these agents. In fact, drug prices have been found to be dependent only on what the markets 
will sustain,[1] and as long as the market continues to sustain inflated drug pricing, pharmaceutical 
companies continue to increase the prices by approximately 10% each year.[1] 
The healthcare system finds itself in a crisis of value: increased spending for less efficacious 
cancer therapies. But how does one define and measure value? Value has been defined in many ways. 
Ramsey et al[6] defined value as giving equal weight to the opinions of patients, families, physicians, and 
health insurers on whether the benefits of treatment outweigh the total sum of the resources expended. 
Others have defined value more simply as “health outcomes achieved per dollar spent,”[7] meaning total 
cost not only to the individual, but to society overall. Some take a more patient-centered approach and 
define value according to the ratio of benefits vs risks; however, there is concern that “because individual 
consumers are largely protected from the costs of healthcare goods and services, value equations in 
healthcare are not based on considerations of the total cost of goods and services but on the portion of 
costs borne by the individual consumers.”[2] Given that value is so hard to define, developing tools to 
measure value has been even more difficult: Should measurements be based on societal costs or out-of-
pocket costs? Does one define efficacy in terms of PFS, OS, quality of life, or something else? How does 
one account for patient autonomy and personal value systems? Taking these multiple variables associated 
with value (ie, total cost of cancer therapy, clinical efficacy, toxicity, patient preference, etc) into 
consideration has proven challenging. In response, both the American Society of Clinical Oncology 
(ASCO) and the European Society for Medical Oncology (ESMO) have released tools to help oncologists 
measure value. 
This is not the first time that institutions have made attempts to define and measure value. Indeed, 
these efforts have been attempted on a global level for decades. Australia led the charge with the 
development of the Pharmaceutical Benefits Scheme in the early 1990s.[8] The United Kingdom followed 
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with the National Institute for Health and Care Excellence in 1999.[8] France has the Haute Autorité de 
Santé, and Germany has the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen.[8] 
Although the objectives of the organizations are very different, the underlying principle of using 
evidence-based medicine to utilize healthcare resources to their fullest potential are largely shared.[8] 
These organizations contracted with academic and professional external organizations to help them 
undertake their comparative effectiveness research, as well as performing some of the research internally. 
All of these organizations incorporated cost concerns into their studies. In all cases, these organizations 
were met with “intense controversy” and “negative press.”[8] Developing such an organization in the 
United States has been extremely difficult, and many that were developed over the years are no longer 
operational. With the American Recovery and Reinvestment Act of 2009, funds were established for the 
development of comparative effectiveness research, but these were restricted in studies of cost because of 
largely politically driven publicity concerning so-called “death panels” and fear of healthcare rationing. 
Thus, in the United States, implementing changes through health policy channels has been slow and 
therefore unsuccessful in reducing the prices of cancer drugs thus far. 
Although the problem of healthcare costs is typically viewed only on the national level, the 
dramatic rise in the cost of healthcare has become a global issue. To truly control costs and provide value 
in cancer care and healthcare overall, an international institutional collaboration may be needed to work 
together in designing and funding comparative effectiveness trials that can obtain the data needed to make 
informed decisions. 
As opposed to health policy, another approach to the value crisis has been to focus on the patient-
physician relationship and the communication of value to patients. The medical community, through such 
organizations as ASCO and ESMO, are taking leadership roles in the efforts to increase the value of 
cancer care.[9,10] ASCO released a paper in 2014 calling on the oncology community to “raise the bar” 
in defining clinically meaningful outcomes in trials.[11] With larger trials, smaller statistically significant 
benefits of therapies were able to be detected. The drugs tested in such trials were being approved and 
incorporated into guidelines while bearing hefty price tags for minimal therapeutic benefit. By the 
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summer of 2015, both ESMO and ASCO had released tools to help oncologists assess value of cancer 
therapy regimens.[9,10] Although these tools are in their infancy, they have started the conversation 
among oncologists on how best to discuss and provide value in cancer care. One challenge that has arisen 
is that the tools are only as strong as the data supporting them. The possibility of weak or uneven data 
raises concerning questions about the comparison of regimens across trials in order to assign value to 
cancer treatments. However, developing these tools and starting the discussion on how oncologists can 
help protect patients and families from the financial toxicity of cancer therapy are sorely needed first 
steps. 
Until the value tools can be refined and until health policy organizations are able to better guide 
physicians and patients through effective care, how are physicians to navigate the communication of 
value to their patients? One possible way to help decrease patient out-of-pocket costs is to use a 
multidisciplinary team that includes a financial counselor who can obtain out-of-pocket cost information 
for patients prior to administration of chemotherapy. This will allow the healthcare team to have a more 
informed value conversation with the patient concerning both out-of-pocket costs and the efficacy of 
therapy, and will provide time to seek out financial aid for patients and families who are in need. In 
addition, physicians should be mindful of expensive imaging modalities, and should use less expensive 
imaging modalities when appropriate and decrease the frequency of imaging when possible. Another 
suggestion, which may be one of the most important things a physician can do to help in providing value 
care to patients, is to ask patients how they are coping financially. It is important to keep the lines of 
communication open with regard to the patient’s out-of-pocket costs. Although these conversations are 
challenging, and may be foreign to many physicians, framing the conversation so that patients understand 
that the physician is concerned about all facets of their well-being may help open the discussion in a 
nonthreatening way. In addition, physicians should try to reduce the use of therapies that have little to no 
evidence to support their use, but instead look to find appropriate clinical trials for patients.[12] If 
oncologists can be mindful of the cost concerns of their patients, they may be able to mitigate, albeit in a 
small way, the value crisis in cancer therapy. 
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Ethics discussions concerning value in cancer care are key to helping resolve this crisis in 
distributive justice and in rationing limited resources in ethical ways. Solutions will require many 
stakeholders coming to the table to discuss value and allocation. Greater emphasis will need to be placed 
on comparative effectiveness data. Until significant strides can be made in health policy, oncologists can 
play a small role in being good stewards of resources and having open discussions with patients 
concerning out-of-pocket costs and expected benefits of therapies. 
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Key Points: 
• The rising cost of cancer therapies is bringing the issue of financial toxicity to the forefront of 
oncology, particularly how it affects patients, taxpayers, and the health system in general. 
• The definition of value in cancer care is still ambiguous; ASCO and ESMO have recently 
released tools that have initiated the conversation on how to provide the best value in cancer care. 
• Involving a multidisciplinary team in the care of cancer patients can help keep them informed and 
aware of the value issues surrounding every aspect of their treatment; in addition, oncologists 
need to keep the lines of communication open about out-of-pocket costs. 
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